Abstract
Although type 2 diabetes mellitus (T2DM) and Alzheimer’s disease (AD) are two independent diseases, evidences from epidemiological, pathophysiological and animal studies have indicated a close pathophysiological relationship between these diseases. Due to the pathophysiological similarity of T2DM and AD, which includes insulin resistance and deficiency, protein aggregation, oxidative stress, inflammation, autophagocytosis and advanced glycation end products; AD is often referred to as “type 3 diabetes”. In addition to the targeted regimens usually used for treating T2DM and AD individually, currently, anti-diabetic drugs are successfully used to reduce the cognitive decline in AD patients. Therefore, if a common pathophysiology of T2DM and AD could be clearly determined, both diseases could be managed more efficiently, possibly by shared pharmacotherapy in addition to understanding the broader spectrum of preventive strategies. The aim of this review is to discuss the pathophysiological bridge between T2DM and AD to lay the foundation for the future treatment strategies in the management of both diseases.
Keywords: Type 2 diabetes mellitus, Alzheimer’s disease, pathophysiology, linkage, inflammation, oxidative stress, treatment.
Current Pharmaceutical Design
Title:Type 2 Diabetes Mellitus and Alzheimer’s Disease: Bridging the Pathophysiology and Management
Volume: 22 Issue: 28
Author(s): Fahmida Alam, Md. Asiful Islam, Teguh Haryo Sasongko and Siew Hua Gan
Affiliation:
Keywords: Type 2 diabetes mellitus, Alzheimer’s disease, pathophysiology, linkage, inflammation, oxidative stress, treatment.
Abstract: Although type 2 diabetes mellitus (T2DM) and Alzheimer’s disease (AD) are two independent diseases, evidences from epidemiological, pathophysiological and animal studies have indicated a close pathophysiological relationship between these diseases. Due to the pathophysiological similarity of T2DM and AD, which includes insulin resistance and deficiency, protein aggregation, oxidative stress, inflammation, autophagocytosis and advanced glycation end products; AD is often referred to as “type 3 diabetes”. In addition to the targeted regimens usually used for treating T2DM and AD individually, currently, anti-diabetic drugs are successfully used to reduce the cognitive decline in AD patients. Therefore, if a common pathophysiology of T2DM and AD could be clearly determined, both diseases could be managed more efficiently, possibly by shared pharmacotherapy in addition to understanding the broader spectrum of preventive strategies. The aim of this review is to discuss the pathophysiological bridge between T2DM and AD to lay the foundation for the future treatment strategies in the management of both diseases.
Export Options
About this article
Cite this article as:
Alam Fahmida, Islam Asiful Md., Sasongko Haryo Teguh and Gan Hua Siew, Type 2 Diabetes Mellitus and Alzheimer’s Disease: Bridging the Pathophysiology and Management, Current Pharmaceutical Design 2016; 22 (28) . https://dx.doi.org/10.2174/1381612822666160527160236
DOI https://dx.doi.org/10.2174/1381612822666160527160236 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mangrove Plants as a Source of Bioactive Compounds: A Review
The Natural Products Journal Pre-feasibility Study for Establishing Radioisotope and Radiopharmaceutical Production Facilities in Developing Countries
Current Radiopharmaceuticals The Role of PEDF in Tumor Growth and Metastasis
Current Molecular Medicine Neurokinin-1 Receptor (NK-1R) Antagonists: Potential Targets in the Treatment of Glioblastoma Multiforme
Current Medicinal Chemistry Herbal Drugs to Targets in the Treatment of Cancer - A Futuristic Approach
Current Cancer Therapy Reviews Nanoemulsion Strategy for Ursolic and Oleanic Acids Isolates from Plumeria Obtusa Improves Antioxidant and Cytotoxic Activity in Melanoma Cells
Anti-Cancer Agents in Medicinal Chemistry Tumour Re-Differentiation Effect of Retinoic Acid: A Novel Therapeutic Approach for Advanced Thyroid Cancer
Current Pharmaceutical Design NPY and NPY Receptors in Vascular Remodeling
Current Topics in Medicinal Chemistry The Role of Neuronal Insulin/Insulin-Like Growth Factor-1 Signaling for the Pathogenesis of Alzheimer’s Disease: Possible Therapeutic Implications
CNS & Neurological Disorders - Drug Targets The Role of Mitochondria in Brain Aging and the Effects of Melatonin
Current Neuropharmacology Effect of Oil Extract from Microalgae (<i>Schizochytrium</i> sp.) on the Viability and Apoptosis of Human Osteosarcoma Cells
Current Pharmaceutical Biotechnology Acetylcholinesterase Inhibitors as Disease-Modifying Therapies for Alzheimers Disease
Current Medicinal Chemistry Ladostigil: A Novel Multimodal Neuroprotective Drug with Cholinesterase and Brain-Selective Monoamine Oxidase Inhibitory Activities for Alzheimers Disease Treatment
Current Drug Targets The Immunoregulatory Protein Human B7H3 is a Tumor-Associated Antigen that Regulates Tumor Cell Migration and Invasion
Current Cancer Drug Targets Anionic Host Defence Peptides from the Plant Kingdom: Their Anticancer Activity and Mechanisms of Action
Protein & Peptide Letters Strategies to Overcome Drug Resistance of Receptor Tyrosine Kinaseaddicted Cancer Cells
Current Medicinal Chemistry Nitric Oxide Releasing Nanomaterials for Cancer Treatment: Current Status and Perspectives
Current Topics in Medicinal Chemistry Voltage Gated ion Channels: Targets for Anticonvulsant Drugs
Current Topics in Medicinal Chemistry Neuropeptide Y1 and Y5 Receptor Antagonists as Potential Anti-Obesity Drugs: Current Status
Mini-Reviews in Medicinal Chemistry Chinese Herbs and Herbal Extracts for Neuroprotection of Dopaminergic Neurons and Potential Therapeutic Treatment of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets